Lycium barbarum polysaccharide chewable tablet for relieving chronic fatigue syndrome
By developing chewable tablets of wolfberry polysaccharide and using the combination of wolfberry polysaccharide and auxiliary materials, the problem of insufficient effective agents to alleviate chronic fatigue syndrome is solved, and the rapid, convenient and efficient relief effect is achieved, which is suitable for a variety of patient groups.
Patent Information
- Application Number
- CN202410430832.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-10
- Publication Date
- 2024-12-10
- Estimated Expiration
- 2044-04-10
AI Technical Summary
The prior art has insufficient effective agents in alleviating chronic fatigue syndrome, and the efficacy of traditional Chinese medicine has not been fully developed, resulting in patients not being accurately diagnosed or misdiagnosed as other diseases.
Develop a chewable tablet of wolfberry polysaccharide containing 20-30% wolfberry polysaccharide and pharmaceutically acceptable auxiliary materials. The wolfberry polysaccharide is extracted by ultrasonic assisted method or enzymatic method, and combined with lubricants, sweeteners and sour taste agents, and is prepared to be suitable for relief. Drugs for chronic fatigue syndrome.
Lycium barbarum polysaccharide chewable tablets are sweet and sour, easy to carry, fast absorption and high bioavailability, which significantly alleviates the symptoms of chronic fatigue syndrome and improves the utilization value of Lycium barbarum polysaccharide. They are suitable for a variety of patient groups.
Smart Images
Figure CN118286169B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a wolfberry polysaccharide chewable tablet for relieving chronic fatigue syndrome. Background Art
[0002] Chronic Fatigue Syndrome (CFS) is a disease with complex symptoms and its location is closely related to various internal organs. Its main feature is persistent fatigue, which cannot be significantly improved after rest. The occurrence of CFS is often accompanied by symptoms such as headache, memory loss, muscle pain, insomnia, etc., which cause great trouble to people's life and study. The prevalence of CFS in various countries around the world is between 0.4% and 2.6%. The incidence rate is usually higher in women than in men, and higher in mental workers than in physical workers. With the acceleration of the pace of life, people's stress is gradually increasing. Long-term sitting, lack of exercise, and irregular sleep can all lead to the occurrence of chronic fatigue syndrome. Nowadays, there are more and more CFS patients, and the incidence rate is increasing year by year, and the development trend is also expanding from cities to rural areas. Because the cause and mechanism of CFS have not yet been clarified, and the diagnostic standards are not unified, 91% of people have not been diagnosed with CFS or have been diagnosed with other diseases.
[0003] At present, the main methods recognized to relieve CFS can be summarized into two categories: cognitive behavioral therapy and graded exercise therapy. Drug intervention is mainly symptomatic support, among which traditional Chinese medicine has a more significant effect. Many studies have shown that traditional Chinese medicine and some traditional Chinese medicine therapies can improve CFS symptoms to varying degrees and are favored in the clinical stage. Therefore, it is very necessary to explore and develop more safe, reliable and effective drugs suitable for CFS. Summary of the invention
[0004] Based on the above content, the present invention provides a Lycium barbarum polysaccharide chewable tablet for relieving chronic fatigue syndrome.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] One of the technical solutions of the present invention is a Lycium barbarum polysaccharide chewable tablet for relieving chronic fatigue syndrome. The raw materials include 20-30% of Lycium barbarum polysaccharide and the remainder of pharmaceutically acceptable excipients by mass percentage.
[0007] The second technical solution of the present invention is the use of Lycium barbarum polysaccharides in the preparation of drugs for relieving chronic fatigue syndrome.
[0008] The present invention discloses the following technical effects:
[0009] The wolfberry polysaccharide chewable tablet of the present invention has a sweet and sour taste, is easy to take and carry, does not need to be taken with water, does not need to be disintegrated, has a fast absorption speed, and has a fast drug dissolution, and is more suitable for children, the elderly and patients with dysphagia.
[0010] The wolfberry polysaccharide chewable tablet of the present invention has strong medicinal effect, can be directly used to relieve chronic fatigue syndrome, and greatly improves bioavailability.
[0011] The present invention finds that Lycium barbarum polysaccharide has the effect of alleviating chronic fatigue syndrome, develops new uses of Lycium barbarum polysaccharide, and improves the utilization value of Lycium barbarum polysaccharide. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0013] Figure 1 This is the effect of the wolfberry polysaccharide of the present invention on SOD in mouse serum.
[0014] Figure 2 This is the effect of the Lycium barbarum polysaccharide of the present invention on MDA in mouse serum.
[0015] Figure 3 This is the effect of the wolfberry polysaccharide of the present invention on GSH-PX in mouse serum.
[0016] Figure 4 This is the effect of the Lycium barbarum polysaccharide of the present invention on CAT in mouse serum. DETAILED DESCRIPTION
[0017] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0018] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0019] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0020] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.
[0021] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0022] The "%" described in the present invention, unless otherwise specified, refers to mass percentage.
[0023] The first aspect of the present invention provides a Lycium barbarum polysaccharide chewable tablet for relieving chronic fatigue syndrome. The raw materials include 20-30% of Lycium barbarum polysaccharide and the remainder of pharmaceutically acceptable excipients by mass percentage.
[0024] In a preferred embodiment of the present invention, the pharmaceutically acceptable excipients include at least one of a lubricant, a sweetener, a sour agent and a filler.
[0025] In a preferred embodiment of the present invention, the raw materials include, by mass percentage, 20-30% of wolfberry polysaccharides, 1-1.5% of lubricant, 22-25% of sweetener, 2-4% of sour agent and the remainder of filler.
[0026] The acidulant used in the specific embodiment of the present invention may be citric acid, the lubricant may be PEG-6000, the filler may be soluble starch, and the sweetener may be sucralose; the present invention has conducted corresponding single factor experiments on the types of the acidulant (citric acid), lubricant (PEG-6000), filler (soluble starch) and sweetener (sucralose) to determine their types, so the acidulant, lubricant, filler and sweetener provided by this study have better effects than other excipients commonly used in the art.
[0027] In a preferred embodiment of the present invention, the raw materials include, by mass percentage, 25% of wolfberry polysaccharides, 1.2% of lubricant, 24% of sweetener, 3% of sour agent and the remainder of filler.
[0028] In a preferred embodiment of the present invention, the wolfberry polysaccharide is extracted from wolfberry by ultrasound-assisted method or enzymatic method.
[0029] In a preferred embodiment of the present invention, the ultrasound-assisted method is specifically:
[0030] The wolfberry is dried and crushed, mixed with anhydrous ethanol for ultrasonic-assisted extraction, condensed and refluxed, and then ultrafiltered to obtain a filter residue; the filter residue is mixed with water for extraction and then ultrafiltered to obtain a filtrate; the filtrate is concentrated and mixed with anhydrous ethanol for precipitation, and the protein in the precipitate is removed to obtain the wolfberry polysaccharide.
[0031] In a preferred embodiment of the present invention, the enzymatic hydrolysis method is specifically:
[0032] The wolfberry is mixed with a composite enzyme and then enzymolyzed to obtain the wolfberry polysaccharide.
[0033] In a preferred embodiment of the present invention, the composite enzyme is a mixture of pectinase: cellulase: papain in a mass ratio of 1:1:0.5; the preparation method of the composite enzyme is as follows: pectinase, cellulase and papain are respectively prepared into 1% solutions and mixed according to the mass ratio of pectinase (3,000U / g): cellulase (2,000U / g): papain (103,000U / g) (purchased from: Shenzhen Jiahe Xuri Trading Co., Ltd.) of 1:1:0.5 to obtain a composite enzyme; in actual use, pectinase, cellulase and papain can be respectively prepared into 1% solutions and added to the reaction system according to the mass ratio of pectinase: cellulase: papain of 1:1:0.5.
[0034] In a preferred embodiment of the present invention, the specific parameters of the enzymatic hydrolysis are: the enzymatic hydrolysis time is 34.72 min, the enzymatic hydrolysis temperature is 35.58° C., and the added amount of the complex enzyme is 0.96% of the mass of the wolfberry.
[0035] The present invention uses ultrasound-assisted method and enzymatic hydrolysis method to obtain two kinds of Lycium barbarum polysaccharides and combines them with relevant auxiliary materials to prepare two kinds of chewable tablets. The C57BL / 6J mouse model of chronic fatigue syndrome is used to verify its effect on relieving CFS, and finally achieves the effect of relieving chronic fatigue syndrome. The use of Lycium barbarum polysaccharides plays a crucial role in relieving chronic fatigue syndrome.
[0036] The second aspect of the present invention provides a method for preparing a wolfberry polysaccharide chewable tablet, comprising the following steps: grinding the wolfberry polysaccharide, passing it through a 100-mesh sieve, mixing it with a sweetener, a sour agent, and a filler, adding an appropriate amount of edible alcohol and stirring evenly to form a soft material, that is, when the soft material reaches a state of being able to be kneaded into a ball and falling apart when touched, passing it through an 18-mesh sieve to granulate, drying (the drying temperature is 60°C and the time is 60 minutes), grinding it into fine sand and then passing it through a 100-mesh sieve, adding a lubricant and stirring evenly, and pressing it through a tablet press to obtain the wolfberry polysaccharide chewable tablet.
[0037] The two kinds of Lycium barbarum polysaccharide chewable tablets capable of relieving chronic fatigue syndrome provided by the present invention are prepared by combining Lycium barbarum polysaccharides obtained by enzymatic hydrolysis and ultrasound-assisted method with flavor correctives, lubricants and wetting agents. The two kinds of Lycium barbarum polysaccharide chewable tablets have the effect of regulating oxidative stress and thus improving chronic fatigue syndrome.
[0038] The third aspect of the present invention provides the use of Lycium barbarum polysaccharide in the preparation of a drug for alleviating chronic fatigue syndrome.
[0039] In a preferred embodiment of the present invention, the wolfberry polysaccharide is extracted from wolfberry by ultrasound-assisted method or enzymatic method.
[0040] The present invention is further described below by way of examples.
[0041] Example 1
[0042] Step 1, ultrasonic-assisted extraction of wolfberry polysaccharides: weigh the dried fruit of Qaidam wolfberry, dry it and crush it, extract it under ultrasonic assistance at 70°C and 60W for 20 minutes according to the material-liquid ratio of dry fruit weight (g): 90% anhydrous ethanol (mL) = 1:7.5, and condense and reflux for 2 hours. After ultrafiltration, leave the filter residue, the filter residue weight (g): distilled water (mL) = 1:26, extract it in a water bath at 90°C for 4 hours and then ultrafilter it. After the filtrate after ultrafiltration is evaporated to one-fourth of the original volume by a rotary evaporator, take the filtrate (mL): anhydrous ethanol (mL) = 1:4, precipitate overnight, and the resulting precipitate is the polysaccharide. Take out the polysaccharide and pour it into an appropriate amount of distilled water to fully dissolve it, remove the protein by the Sevage method, and freeze-dry to obtain wolfberry polysaccharide.
[0043] Step 2, extracting Lycium barbarum polysaccharides by enzymatic hydrolysis: optimizing the enzymatic hydrolysis extraction process of Lycium barbarum polysaccharides around enzymatic hydrolysis time, compound enzyme ratio (1% pectinase solution, 1% cellulase solution, 1% papain solution mass ratio = 1:1:0.5), enzyme addition ratio, enzymatic hydrolysis temperature, centrifugal speed, dynamic adsorption speed (shaking table speed), material-liquid ratio and adsorption time, evaluating the optimization of the enzymatic hydrolysis process, and determining the optimal enzymatic hydrolysis preparation process of Lycium barbarum polysaccharides. Through response surface optimization, the present invention found that the optimal extraction process of Lycium barbarum polysaccharides is: enzymatic hydrolysis time is 34.72min, enzymatic hydrolysis temperature is 35.58℃, centrifugal speed is 6217r / min, enzyme addition amount is 0.96%, material-liquid ratio is 1:23.66g / mL, adsorption time is 3.72h, and shaking table speed is 107r / min. Under these conditions, the yield of Lycium barbarum polysaccharides is 36.8g / 100g, and the credibility is 0.733. Combined with the actual operation, the enzymatic hydrolysis time was 35min, the enzymatic hydrolysis temperature was 36℃, the centrifugal speed was 6200r / min, the enzyme addition amount was 1%, the solid-liquid ratio was 1:24g / mL, the adsorption time was 3.7h, the shaking speed was 110r / min, and the extraction was performed 3 times. It was found that the average yield of Lycium barbarum polysaccharides was 36.81%, the RSD was 0.155%, and the difference from the predicted value was 0.995%. It shows that the obtained response surface model can accurately and comprehensively predict the yield of Lycium barbarum polysaccharides. The specific steps are as follows: Lycium barbarum is dried in the shade indoors, and Lycium barbarum and distilled water are mixed for 4h at a solid-liquid ratio of 1:8g / mL. After the Lycium barbarum is completely swollen, the distilled water is poured out for standby use, and the Lycium barbarum is completely beaten with a stirrer, and the standby distilled water is poured into the completely beaten Lycium barbarum at a solid-liquid ratio of 1:4g / mL. A mixture of 1% complex enzyme pectinase solution: 1% cellulase solution: 1% papain solution in a mass ratio of 1:1:0.5 was added to wolfberry, and enzymolysis was performed at 36°C for 29 minutes. After filtration, a wolfberry polysaccharide solution was obtained, and the wolfberry polysaccharide solution was centrifuged at a speed of 6150r / min for 5 minutes. The obtained supernatant was mixed with a macroporous adsorption resin AB-8 at a liquid-to-solid ratio of 23:1mL / g, and the mixed supernatant was placed in a shaking table and dynamically adsorbed at a speed of 107r / min for 3.7 hours. The adsorbed wolfberry polysaccharide solution was centrifuged at a speed of 8000r / min for 3 minutes, the macroporous adsorption resin AB-8 was filtered out, and wolfberry polysaccharide was obtained after freeze drying (-80°C, 2.5Pa, 1d).
[0044] Step 3, preparation of Lycium barbarum polysaccharide chewable tablets: single factor experiments were used to screen the range of Lycium barbarum polysaccharide addition, acidulant addition, lubricant addition, filler addition and sweetener addition. Finally, three factors were selected with sensory evaluation and appearance evaluation as evaluation indicators, and a response surface scheme was designed to screen the amount of Lycium barbarum polysaccharide addition, lubricant addition, and sweetener addition in the chewable tablets formula to obtain the optimal formula ratio. The results showed that the optimal process formula was: Lycium barbarum polysaccharide addition was 25%, lubricant addition was 1.2%, sweetener addition was 24%, acidulant addition was 3%, and the remainder was filler. The Lycium barbarum polysaccharide chewable tablets prepared according to this formula have a sweet and sour taste, are uniform in size, and have a faint wolfberry fragrance. The specific preparation process of the wolfberry polysaccharide chewable tablets is as follows: after grinding the wolfberry polysaccharide, passing it through a 100-mesh sieve and mixing it with a sweetener, a sour agent and a filler, adding an appropriate amount of edible alcohol and stirring evenly to form a soft material, that is, when the soft material reaches a state of being kneaded into a ball and falling apart when touched, passing it through an 18-mesh sieve for granulation, drying (drying temperature is 60°C and time is 60min), grinding it into fine sand and passing it through a 100-mesh sieve, adding a lubricant and stirring evenly, and using a tablet press to form wolfberry polysaccharide chewable tablets that can relieve chronic fatigue syndrome.
[0045] Step 4, the quality of the Lycium barbarum polysaccharide chewable tablets is detected by weight difference, friability, hardness, pH detection, conventional physical and chemical indicators, and microbial indicators. The physical and chemical indicators are in accordance with GB5009.3, GB5009.4, GB5009.12, GB5009.11 and GB5009.17. The content of moisture, ash, lead, arsenic and mercury in the Lycium barbarum polysaccharide chewable tablets was detected. The microbial indicators were in accordance with GB4789.2, GB4789.3, GB4789.15, GB4789.4, GB4789.5 and GB4789.10. The content of total colonies, Escherichia coli, mold, Salmonella, Shigella and Staphylococcus aureus contained in the Lycium barbarum polysaccharide chewable tablets was detected. The results show that the Lycium barbarum polysaccharide chewable tablets finally prepared in this embodiment meet the relevant provisions of the 2020 edition of the "Chinese Pharmacopoeia".
[0046] Effect verification example
[0047] In order to clarify the improvement effect of Qaidam Lycium barbarum polysaccharide and chewable tablets on chronic fatigue syndrome, the present invention adopts a chronic fatigue syndrome model of intraperitoneal injection of lipopolysaccharide combined with swimming experimental mice to verify the effect of Lycium barbarum polysaccharide and chewable tablets obtained by ultrasound-assisted method and enzymatic hydrolysis method on relieving CFS. The specific experimental materials for the study are as follows:
[0048] 1. Experimental Materials
[0049] (1) Drugs: Two kinds of Lycium barbarum polysaccharide chewable tablets prepared by the present invention, each weighing 0.502±0.007, coenzyme Q10 (Eisai (China) Pharmaceutical Co., Ltd., national approval number: H10930021)
[0050] (2) Experimental animals: C57BL / 6J mice (male), SPF grade, Chongqing Tengxin Biotechnology Co., Ltd. Xi'an Branch; SPF mouse maintenance feed, Chongqing Tengxin Biotechnology Co., Ltd. Xi'an Branch
[0051] (3) Reagents: Catalase kit (A007-1-1), superoxide dismutase kit (A001-3-2), malondialdehyde kit (A003-1-2), glutathione peroxidase kit (A005-1), Nanjing Jiancheng Bioengineering Institute.
[0052] 2. Experimental methods and results
[0053] This experiment used 88 C57BL / 6J mice aged four weeks, maintained in a 12 / 12h light / dark cycle, and had free access to normal food and water. After one week of adaptive training, the mice were randomly divided into 11 groups:
[0054] The blank group (NC, n=8) was given an equal amount of 0.9% saline by gavage; the model group (MC, n=8) was given an equal amount of 0.9% saline by gavage, and 3 mg / kg lipopolysaccharide was intraperitoneally injected on the 28th day combined with a 20-min swimming test. The positive drug control group (CoQ10, n=8) was given 10 mg / kg / d CoQ10 capsules by gavage; the ultrasound-assisted low-dose Lycium barbarum polysaccharide group (LAL, n=8) was given 120 mg / kg / d Lycium barbarum polysaccharide by gavage; the ultrasound-assisted high-dose Lycium barbarum polysaccharide group (LAH, n=8) was given 360 mg / kg / d Lycium barbarum polysaccharide by gavage; the ultrasound-assisted low-dose Lycium barbarum polysaccharide chewable tablet group (LALJ, n=8) was given 480 mg / kg / d Lycium barbarum polysaccharide chewable tablet by gavage; the ultrasound-assisted high-dose Lycium barbarum polysaccharide chewable tablet group (LAHJ, n=8) was given 1 440mg / kg / d of Lycium barbarum polysaccharide chewable tablets; low-dose group of enzymatic Lycium barbarum polysaccharide (LBL, n=8) was intragastrically administered with 120mg / kg / d of Lycium barbarum polysaccharide; high-dose group of enzymatic Lycium barbarum polysaccharide (LBH, n=8) was intragastrically administered with 360mg / kg / d of Lycium barbarum polysaccharide; low-dose group of enzymatic Lycium barbarum polysaccharide chewable tablets (LBLJ, n=8) was intragastrically administered with 480mg / kg / d of Lycium barbarum polysaccharide chewable tablets; high-dose group of enzymatic Lycium barbarum polysaccharide chewable tablets (LBHJ, n=8) was intragastrically administered with 1 440mg / kg / d of Lycium barbarum polysaccharide chewable tablets.
[0055] After continuous intervention of C57BL / 6J mice for 28 days, all groups except the blank group were intraperitoneally injected with 3 mg / kg lipopolysaccharide and subjected to a 20-min swimming test. The C57BL / 6J mice were anesthetized with an appropriate amount of ether and blood was collected from the eye sockets. The blood samples were centrifuged at 3 500 rpm for 10 min at 4°C to separate serum. The levels of CAT, SOD, MDA, and GSH-PX in mouse serum were determined according to the kit assay method. The results are as follows:
[0056] Figure 1 The effect of Lycium barbarum polysaccharide on SOD in mouse serum; SOD is an antioxidant metal enzyme existing in the body, which plays a role in balancing oxidation and anti-oxidation in the body. It plays a vital role in some immune diseases and inflammation. Figure 1 It can be seen that the effects of two different extraction methods of Lycium barbarum polysaccharides on SOD in mice are as follows: compared with the model group, there is no significant difference in the positive drug coenzyme Q10 and low-dose Lycium barbarum polysaccharides by enzymatic hydrolysis; the SOD level of low-dose Lycium barbarum polysaccharides by ultrasound-assisted method, low-dose Lycium barbarum polysaccharides chewable tablets by ultrasound-assisted method and high-dose Lycium barbarum polysaccharides chewable tablets by enzymatic hydrolysis method increased significantly (P < 0.05); the SOD level of high-dose Lycium barbarum polysaccharides chewable tablets by enzymatic hydrolysis method, high-dose Lycium barbarum polysaccharides by ultrasound-assisted method, high-dose Lycium barbarum polysaccharides by enzymatic hydrolysis method and high-dose Lycium barbarum polysaccharides chewable tablets by ultrasound-assisted method increased significantly (P < 0.01). From the results of SOD, it can be analyzed that the effects of Lycium barbarum polysaccharides obtained by ultrasound-assisted method and enzymatic hydrolysis method on SOD are not significantly different, and compared with the model group, both can significantly increase the level of SOD in mice, thereby achieving the effect of alleviating chronic fatigue syndrome.
[0057] Figure 2 The effect of Lycium barbarum polysaccharide on MDA in mouse serum; MDA is a product of lipid peroxidation. When the MDA level increases, it will cause damage to cells and tissues due to oxidation. At the same time, MDA content is also an important parameter of the body's antioxidant capacity. It can intuitively express the rate of lipid peroxidation and the degree of damage to tissues and cells due to peroxidation. Figure 2It can be seen that the effects of two different extraction methods of Lycium barbarum polysaccharides on MDA in mice are as follows: compared with the model group, the MDA levels of positive drug coenzyme Q10, ultrasound-assisted low-dose Lycium barbarum polysaccharides, enzymatic low-dose Lycium barbarum polysaccharides, ultrasound-assisted low-dose Lycium barbarum polysaccharides chewable tablets, ultrasound-assisted high-dose Lycium barbarum polysaccharides, and ultrasound-assisted high-dose Lycium barbarum polysaccharides chewable tablets were significantly reduced (P < 0.01); the MDA level of high-dose Lycium barbarum polysaccharides by enzymatic hydrolysis was significantly reduced (P < 0.05). From the results of MDA, it can be analyzed that Lycium barbarum polysaccharides and chewable tablets obtained by the two extraction methods can significantly reduce the level of MDA in mice, thereby achieving the effect of alleviating chronic fatigue syndrome, and compared with the enzymatic hydrolysis method, the Lycium barbarum polysaccharides and chewable tablets obtained by ultrasound-assisted extraction have better effects.
[0058] Figure 3 Effect of Lycium barbarum polysaccharides on GSH-PX in mouse serum; GSH-PX is an important peroxide decomposing enzyme, which is also widely present in the body. Its main function is to catalyze the conversion of GSH into GSSG, converting toxic peroxides into non-toxic hydroxyl compounds, thereby protecting the body from damage by peroxides. Figure 3 It can be seen that the effects of two different extraction methods of Lycium barbarum polysaccharides on GSH-PX in mice are as follows: compared with the model group, the positive drug coenzyme Q10, ultrasound-assisted low-dose Lycium barbarum polysaccharides, enzymatic low-dose Lycium barbarum polysaccharides, ultrasound-assisted low-dose Lycium barbarum polysaccharides chewable tablets, ultrasound-assisted high-dose Lycium barbarum polysaccharides, enzymatic high-dose Lycium barbarum polysaccharides, ultrasound-assisted high-dose Lycium barbarum polysaccharides chewable tablets, and enzymatic high-dose Lycium barbarum polysaccharides chewable tablets GSH-PX levels were significantly increased (P < 0.01); the enzymatic low-dose Lycium barbarum polysaccharides chewable tablets GSH-PX level was significantly increased (P < 0.05). From the results of GSH-PX, it can be analyzed that Lycium barbarum polysaccharides and chewable tablets obtained by the two extraction methods can significantly increase the level of GSH-PX in mice, thereby achieving the effect of alleviating chronic fatigue syndrome, and compared with the enzymatic method, the ultrasound-assisted Lycium barbarum polysaccharides and chewable tablets have better effects.
[0059] Figure 4 The effect of Lycium barbarum polysaccharide on CAT in mouse serum; CAT is an enzyme that decomposes hydrogen peroxide into water and oxygen, preventing it from further generating hydroxyl free radicals to cause harm to the body, and plays an extremely important role in the growth and metabolism of the body. Figure 4It can be seen that the effects of two different extraction methods of Lycium barbarum polysaccharides on mouse CAT are as follows: compared with the model group, the positive drug coenzyme Q10, ultrasound-assisted low-dose Lycium barbarum polysaccharides, enzymatic low-dose Lycium barbarum polysaccharides, ultrasound-assisted low-dose Lycium barbarum polysaccharides chewable tablets, enzymatic low-dose Lycium barbarum polysaccharides chewable tablets, ultrasound-assisted high-dose Lycium barbarum polysaccharides, ultrasound-assisted high-dose Lycium barbarum polysaccharides chewable tablets, and enzymatic high-dose Lycium barbarum polysaccharides chewable tablets significantly increased CAT levels (P < 0.01); the enzymatic high-dose Lycium barbarum polysaccharides GSH-PX level increased significantly (P < 0.05). From the results of CAT, it can be analyzed that compared with ultrasound-assisted, the Lycium barbarum polysaccharides and chewable tablets obtained by enzymatic hydrolysis have better effects.
[0060] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. Use of Lycium barbarum polysaccharide in the preparation of a drug for relieving chronic fatigue syndrome, It is characterized in that Calculated by mass percentage, the raw materials of the drug for relieving chronic fatigue syndrome include 20-30% of wolfberry polysaccharide, 1-1.5% of lubricant, 22-25% of sweetener, 2-4% of sour agent and the balance of filler; The acidulant is citric acid; the lubricant is PEG-6000; the filler is soluble starch; and the sweetener is sucralose; The wolfberry polysaccharide is extracted from wolfberry by ultrasound-assisted method or enzymatic method; The ultrasound-assisted method is specifically: The wolfberry is dried and crushed, mixed with anhydrous ethanol for ultrasonic-assisted extraction, condensed and refluxed, and then ultrafiltered to obtain a filter residue; the filter residue is mixed with water for extraction and then ultrafiltered to obtain a filtrate; the filtrate is concentrated and then mixed with anhydrous ethanol for precipitation, and the protein in the precipitate is removed to obtain the wolfberry polysaccharide; The enzymatic hydrolysis method is specifically: The wolfberry is mixed with a composite enzyme and then subjected to enzymolysis to obtain the wolfberry polysaccharide; The dosage form of the medicine for relieving chronic fatigue syndrome is a chewable tablet.
2. The use according to claim 1, It is characterized in that Calculated by mass percentage, the raw materials include 25% wolfberry polysaccharides, 1.2% lubricant, 24% sweetener, 3% acidulant and the remainder filler.
3. The use according to claim 1, It is characterized in that The composite enzyme is a mixture of pectinase: cellulase: papain in a mass ratio of 1:1:0.5; the temperature of the enzymolysis is 35.58°C and the time is 34.72 min; the added amount of the composite enzyme is 0.96% of the mass of the wolfberry.